help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2006-2388
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by El Fassi, D.
Right arrow Articles by Hegedüs, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by El Fassi, D.
Right arrow Articles by Hegedüs, L.
Related Collections
Right arrow Thyroid
Right arrow Autoimmunity
The Journal of Clinical Endocrinology & Metabolism Vol. 92, No. 5 1769-1772
Copyright © 2007 by The Endocrine Society


BRIEF REPORT

B Lymphocyte Depletion with the Monoclonal Antibody Rituximab in Graves’ Disease: A Controlled Pilot Study

Daniel El Fassi, Claus H. Nielsen, Steen J. Bonnema, Hans C. Hasselbalch and Laszlo Hegedüs

Department of Endocrinology and Metabolism (D.E.F., S.J.B., L.H.), Odense University Hospital, 5000 Odense, Denmark; Institute for Inflammation Research (D.E.F., C.H.N.), Rigshospitalet National University Hospital, 2100 Copenhagen, Denmark; and Department of Hematology (H.C.H.), Odense University Hospital, 5000 Odense, Denmark

Address all correspondence and requests for reprints to: Laszlo Hegedüs, Department of Endocrinology and Metabolism, Odense University Hospital, Sdr. Boulevard 29, DK-5000 Odense, Denmark. E-mail: laszlo.hegedus{at}ouh.regionsyddanmark.dk.

Context: Graves’ disease (GD) is a common TSH receptor autoantibody (TRAb)-mediated disorder. Because B lymphocytes are important self-antigen presenting cells and precursors for antibody-secreting plasma cells, temporary B-lymphocyte depletion with the monoclonal antibody rituximab (RTX) might be of benefit in GD.

Objective/Design: The objective of this prospective, controlled, nonrandomized study was to investigate the effect of RTX in GD.

Setting/Patients: We studied 20 outpatients referred to a university clinic with newly diagnosed (four with relapse) untreated GD. Ten received RTX (+RTX), whereas 10 did not (–RTX).

Intervention: The patients received methimazole (MMI) for a median of 102 d (+RTX) and 110 d (–RTX) before the study. Patients in the +RTX group received 375 mg RTX/m2 iv on d 1, 8, 15, and 22, and all patients were withdrawn from methimazole (MMI) at d 22.

Main Outcome Measures: We measured time to relapse of hyperthyroidism and changes in autoantibody levels.

Results: Four patients in the +RTX group remained in remission with a median follow-up of 705 d (range, 435–904 d), whereas all the patients in the –RTX group had relapsed by d 393 (P < 0.05). All of the patients in remission had initial TRAb levels below 5 IU/liter (normal, <0.7 IU/liter). However, none of the five patients in the –RTX group with correspondingly low TRAb levels were in remission (P < 0.01). RTX treatment did not affect autoantibody levels to a greater extent than did MMI monotherapy. Two patients received glucocorticoids for joint pain after RTX therapy.

Conclusions: RTX treatment may induce sustained remission in patients with GD with low TRAb levels. However, RTX did not affect autoantibody levels and seems ineffective in patients with high TRAb levels. At present, high cost, low efficacy, and potential side effects do not support use in uncomplicated GD.




This article has been cited by other articles:


Home page
Arch OphthalmolHome page
R. S. Douglas, A. Tsirbas, M. Gordon, D. Lee, N. Khadavi, H. C. Garneau, R. A. Goldberg, K. Cahill, P. J. Dolman, V. Elner, et al.
Development of Criteria for Evaluating Clinical Response in Thyroid Eye Disease Using a Modified Delphi Technique
Arch Ophthalmol, September 1, 2009; 127(9): 1155 - 1160.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. V. Misharin, Y. Nagayama, H. A. Aliesky, Y. Mizutori, B. Rapoport, and S. M. McLachlan
Attenuation of Induced Hyperthyroidism in Mice by Pretreatment with Thyrotropin Receptor Protein: Deviation of Thyroid-Stimulating to Nonfunctional Antibodies
Endocrinology, August 1, 2009; 150(8): 3944 - 3952.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
H. G. Raterman, S. Simsek, W. F. Lems, E. W. Meesters, B. A. C. Dijkmans, and M. T. Nurmohamed
Rituximab and Thyroid Function
Arch Intern Med, June 8, 2009; 169(11): 1073 - 1074.
[Full Text] [PDF]


Home page
Eur J EndocrinolHome page
K. A Heemstra, R. E Toes, J. Sepers, A. M Pereira, E. P Corssmit, T. W J Huizinga, J. A Romijn, and J. W Smit
Rituximab in relapsing Graves' disease, a phase II study
Eur. J. Endocrinol., November 1, 2008; 159(5): 609 - 615.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
P. Rodien
Rituximab in Graves' disease
Eur. J. Endocrinol., November 1, 2008; 159(5): 515 - 516.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. S. Anderson
Update in Endocrine Autoimmunity
J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3663 - 3670.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. Kaguelidou, C. Alberti, M. Castanet, M.-A. Guitteny, P. Czernichow, J. Leger, and for the French Childhood Graves' Disease Study Gro
Predictors of Autoimmune Hyperthyroidism Relapse in Children after Discontinuation of Antithyroid Drug Treatment
J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3817 - 3826.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
D. E. Fassi, C. H Nielsen, J. Kjeldsen, O. Clemmensen, and L. Hegedus
Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease
Gut, May 1, 2008; 57(5): 714 - 715.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T. J. Smith
B Cell Depletion in Graves' Disease: The Right Answer to the Wrong Question?
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1620 - 1622.
[Full Text] [PDF]

eLetters:

Read all eLetters

Daclizumab and Graves' ophthalmopathy
Gabriele Rossi
JCEM Online, 6 Mar 2007 [Full text]



HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society